Development of Fractalkine-Targeted Nanofibers that Localize to Sites of Arterial Injury

Atherosclerosis is the leading cause of death and disability around the world, with current treatments limited by neointimal hyperplasia. Our goal was to synthesize, characterize, and evaluate an injectable, targeted nanomaterial that will specifically bind to the site of arterial injury. Our target protein is fractalkine, a chemokine involved in both neointimal hyperplasia and atherosclerosis. We showed increased fractalkine staining in rat carotid arteries 24 h following arterial injury and in the aorta of low-density lipoprotein receptor knockout (LDLR-/-) mice fed a high-fat diet for 16 weeks. Three peptide amphiphiles (PAs) were synthesized: fractalkine-targeted, scrambled, and a backbone PA. PAs were ≥90% pure on liquid chromatography/mass spectrometry (LCMS) and showed nanofiber formation on transmission electron microscopy (TEM). Rats systemically injected with fractalkine-targeted nanofibers 24 h after carotid artery balloon injury exhibited a 4.2-fold increase in fluorescence in the injured artery compared to the scrambled nanofiber (p < 0.001). No localization was observed in the non-injured artery or with the backbone nanofiber. Fluorescence of the fractalkine-targeted nanofiber increased in a dose dependent manner and was observed for up to 48 h. These data demonstrate the presence of fractalkine after arterial injury and the localization of our fractalkine-targeted nanofiber to the site of injury and serve as the foundation to develop this technology further.

[1]  Pablo Ariel,et al.  Light Sheet Fluorescence Microscopy as a New Method for Unbiased Three-Dimensional Analysis of Vascular Injury , 2020, bioRxiv.

[2]  Tristan D. Clemons,et al.  Peptide Amphiphile Supramolecular Nanostructures as a Targeted Therapy for Atherosclerosis. , 2019, Macromolecular bioscience.

[3]  M. Kibbe,et al.  Peptide Amphiphile Nanostructures for Targeting of Atherosclerotic Plaque and Drug Delivery , 2018, Advanced biosystems.

[4]  M. Kibbe,et al.  Targeted Nitric Oxide Delivery by Supramolecular Nanofibers for the Prevention of Restenosis After Arterial Injury. , 2016, Antioxidants & redox signaling.

[5]  B. Lacey,et al.  Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. , 2016, Circulation research.

[6]  Samuel I Stupp,et al.  Tissue-Factor Targeted Peptide Amphiphile Nanofibers as an Injectable Therapy To Control Hemorrhage. , 2016, ACS nano.

[7]  Samuel I Stupp,et al.  Shape-Dependent Targeting of Injured Blood Vessels by Peptide Amphiphile Supramolecular Nanostructures. , 2015, Small.

[8]  J. Bauersachs,et al.  Fractalkine Is Expressed in Early and Advanced Atherosclerotic Lesions and Supports Monocyte Recruitment via CX3CR1 , 2012, PloS one.

[9]  M. Böhm,et al.  Paclitaxcel-coated balloon plus bare metal stent vs. sirolimus-eluting stent in de novo lesions: an IVUS study. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[10]  M. Kibbe,et al.  Insights into the effect of nitric oxide and its metabolites nitrite and nitrate at inhibiting neointimal hyperplasia. , 2011, Nitric oxide : biology and chemistry.

[11]  M. Haurani,et al.  Adventitial fibroblast reactive oxygen species as autacrine and paracrine mediators of remodeling: bellwether for vascular disease? , 2007, Cardiovascular research.

[12]  Hyoung-Tae Kim,et al.  Alpha-lipoic acid inhibits fractalkine expression and prevents neointimal hyperplasia after balloon injury in rat carotid artery. , 2006, Atherosclerosis.

[13]  Rachel W. Kasinskas,et al.  Fractalkine targeting with a receptor-mimicking peptide-amphiphile. , 2005, Biomacromolecules.

[14]  A. Kastrati,et al.  Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. , 2005, JAMA.

[15]  A. Kastrati,et al.  Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs Balloon Angioplasty for Prevention of Recurrences in Patients With Coronary In-Stent Restenosis , 2005 .

[16]  D. Greaves,et al.  Smooth Muscle Cells in Human Atherosclerotic Plaques Express the Fractalkine Receptor CX3CR1 and Undergo Chemotaxis to the CX3C Chemokine Fractalkine (CX3CL1) , 2003, Circulation.

[17]  W. Voelker,et al.  Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism. , 2003, American heart journal.

[18]  P. Debré,et al.  Decreased Atherosclerotic Lesion Formation in CX3CR1/Apolipoprotein E Double Knockout Mice , 2003, Circulation.

[19]  I. Charo,et al.  Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. , 2003, The Journal of clinical investigation.

[20]  A. Quyyumi,et al.  Association Between Polymorphism in the Chemokine Receptor CX3CR1 and Coronary Vascular Endothelial Dysfunction and Atherosclerosis , 2001, Circulation research.

[21]  P. Debré,et al.  Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. , 2001, Blood.

[22]  J. Egido,et al.  HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. , 1998, Journal of the American College of Cardiology.

[23]  P. Libby,et al.  Reduction of atherosclerosis in mice by inhibition of CD40 signalling , 1998, Nature.

[24]  M. Leon,et al.  In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. , 1998, Journal of the American College of Cardiology.

[25]  G. Baumann,et al.  Regulation of Tumor Necrosis Factor-α and Interleukin-1β Induced Adhesion Molecule Expression in Human Vascular Smooth Muscle Cells by cAMP , 1997 .

[26]  G. Baumann,et al.  Regulation of tumor necrosis factor alpha- and interleukin-1-beta-induced induced adhesion molecule expression in human vascular smooth muscle cells by cAMP. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[27]  M. Reidy,et al.  Kinetics of cellular proliferation after arterial injury. III. Endothelial and smooth muscle growth in chronically denuded vessels. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[28]  M. Reidy,et al.  Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. , 1983, Laboratory investigation; a journal of technical methods and pathology.